2026 ICD-10-CM Diagnosis Code A35Other tetanus
ICD-10-CM Codes›A00–B99›A30-A49›A35
- Billable — Valid for Submission
- Not Chronic
ICD-10-CM A35
A35 is a billable ICD-10-CM diagnosis code for other tetanus. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 867 through 869. Coders also document this condition as autonomic disorder due to tetanus. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Bacterial infections.
Code Identity
ICD-10-CM Code
A35
Billable Status
Yes — Valid for Submission
Code Describes
Other tetanus
Chapter
A30-A49
Other bacterial diseases
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Autonomic disorder due to tetanus
- Cephalic tetanus
- Disorder of autonomic nervous system due to infectious disease
- Generalized tetanus
- Infection caused by Clostridium tetani
- Localized tetanus
- Tetanic opisthotonus
- Tetanus
- Tetanus with trismus
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Tetanus NOS
Type 1 Excludes
Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Radiculomyelitis - See Also: Encephalitis;
- Clostridium tetani - A35
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Radiculomyelitis
- toxic, due to
- Clostridium tetani
- Tetanus, tetanic(cephalic) (convulsions)
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
CCSR INF003
Bacterial infections
Default principal diagnosis: inpatient Yes · outpatient Yes
Clinical InformationClinical
Tetanus
a disease caused by tetanospasmin, a powerful protein toxin produced by clostridium tetani. tetanus usually occurs after an acute injury, such as a puncture wound or laceration. generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. it may progress to the generalized form.Tetanus Antitoxin
an antitoxin used for the treatment of tetanus.Tetanus Toxin
protein synthesized by clostridium tetani as a single chain of ~150 kda with 35% sequence identity to botulinum toxin that is cleaved to a light and a heavy chain that are linked by a single disulfide bond. tetanolysin is the hemolytic and tetanospasmin is the neurotoxic principle. the toxin causes disruption of the inhibitory mechanisms of the cns, thus permitting uncontrolled nervous activity, leading to fatal convulsions.Tetanus Toxoid
protein synthesized by clostridium tetani as a single chain of ~150 kda with 35% sequence identity to botulinum toxin that is cleaved to a light and a heavy chain that are linked by a single disulfide bond. tetanolysin is the hemolytic and tetanospasmin is the neurotoxic principle. the toxin causes disruption of the inhibitory mechanisms of the cns, thus permitting uncontrolled nervous activity, leading to fatal convulsions.Clostridium tetani
the cause of tetanus in humans and domestic animals. it is a common inhabitant of human and horse intestines as well as soil. two components make up its potent exotoxin activity, a neurotoxin and a hemolytic toxin.CEA/Tetanus Toxoid T Helper Epitope Fusion Protein-Expressing DNA Plasmid Vaccine|tetwtCEA DNA
a plasmid vaccine encoding wild type human carcinoembryonic antigen (cea) fused to a tetanus toxoid t helper epitope, with potential antineoplastic activity. upon vaccination and subsequent intradermal electroporation, cea/tetanus toxoid t helper epitope fusion protein-expressing dna plasmid vaccine may stimulate the immune system to mount a cytotoxic t-lymphocyte (ctl) response against cea-expressing tumor cells. cea, a tumor associated antigen, is overexpressed in a variety of cancer cell types. the tetanus toxoid helper peptide epitope, obtained from the bacterial clostridium tetani toxoid, binds to class ii mhc molecules and increases the helper t-cell response thereby inducing an increased and long-term immune response.Clostridium tetani Toxin Antibody Measurement|CTETXNAB|Clostridium tetani TeNT Antibody|Clostridium tetani Toxin Antibody|Clostridium tetani Toxin Antibody|Tetanospasmin Antibody|Tetanus Neurotoxin Antibody
the determination of the amount of clostridium tetani toxin antibody present in a sample.Clostridium tetani Toxin|CLOSTRIDIUM TETANI TOXIN|TeNT|Tetanospasmin|Tetanus Toxin
the approximately 150 kda secreted protein toxin and the virulence factor for clostridium tetani.Diphtheria Toxoid/Tetanus Toxoid Vaccine Adsorbed|DT|DT|Diphtheria Toxoid Tetanus Toxoid Vaccine Adsorbed|Diphtheria and Tetanus Toxoids Adsorbed USP (For Pediatric Use)
a vaccine containing detoxified tetanus toxoid and detoxified diphtheria toxoid adsorbed on aluminum phosphate with active immunizing activity against diphtheria and tetanus. intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin and diphtheria toxin.Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Adsorbed, Recombinant Hepatitis B/Inactivated Poliovirus Vaccine Combined|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine|Pediarix
a vaccine consisting of detoxified tetanus toxoid, detoxified diphtheria toxoid, acellular pertussis antigens, inactivated poliovirus (ipv) types 1,2 and 3 and hepatitis b (hbv) surface antigen, with active immunizing activities against diphtheria, tetanus, pertussis, hepatitis b, and poliomyelitis. the acellular pertussis components in this vaccine, produced by bordetella pertussis, are detoxified pertussis toxin (pt), filamentous hemagglutinin (fha) and pertactin (prn). upon intramuscular injection, this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin, b. pertussis antigens, polioviruses and hbv. the diphtheria and tetanus toxoids and pertussis antigens (inactivated pt, fha, and pertactin) are adsorbed onto aluminum hydroxide; the hepatitis b antigen is adsorbed onto aluminum phosphate.Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Adacel|DTaP|DTaP|Daptacel|Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed|Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed|Infanrix|Tripedia
a vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and acellular pertussis antigens, adsorbed on aluminum phosphate, with active immunizing activity against diphtheria, tetanus and pertussis. the acellular pertussis vaccine components, produced by bordetella pertussis, are detoxified pertussis toxin (pt), filamentous hemagglutinin (fha), pertactin (prn) and fimbriae types 2 and 3 (fim). intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin and b. pertussis antigens.Diphtheria Toxoid/Tetanus Toxoid/Inactivated Pertussis Vaccine|DTP|Diphtheria Toxoid/Tetanus Toxoid/Inactivated Pertussis Vaccine DTP
a vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and inactivated pertussis antigens.Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliomyelitis-Haemophilus influenzae Type B Vaccine|DTaP(5)-IPV-Hib|DTaP-IPV-Hib|Pediacel
a vaccine consisting of detoxified diphtheria toxoid (d), detoxified tetanus toxoid (t), acellular pertussis (ap) antigens, inactivated poliovirus (ipv) types 1, 2 and 3, and haemophilus influenzae type b (hib) capsular polysaccharide (polyribosylribitol phosphate; prp) covalently bound to tetanus protein, suspended in water for injection and with active immunizing activity against diphtheria, tetanus, pertussis, poliomyelitis and h. influenzae type b. the five purified pertussis antigens in this vaccine are pertussis toxin (pt), filamentous hemagglutinin (fha), pertactin (prn) and fimbriae types 2 and 3 (fim). upon intramuscular injection of the diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-haemophilus influenzae type b vaccine (dtap-ipv-hib), this vaccine activates the immune system to develop antibodies against diphtheria toxin, tetanus toxin, b. pertussis antigens, polioviruses and hib, thereby providing active immunization against these diseases. the diphtheria and tetanus toxoids and pertussis antigens (inactivated pt, fha, prn and fim) are adsorbed separately onto aluminum phosphate and then combined with ipv and prp.HLA-A2-restricted IL-13Ra2/EphA2/Survivin/Tetanus Toxoid T-helper Epitopes-Montanide 51 Vaccine|HLA-A2-restricted IL-13Ra2/EphA2/Survivin/Tetanus Toxoid T-helper Peptides-Montanide 51 Vaccine
a peptide vaccine comprised of synthetic human leukocyte antigen (hla)-a2-restricted peptides derived from the tumor-associated antigens (taas) interleukin-13 receptor alpha-2 (il-13ra2), the tyrosine kinase receptor ephrin receptor a2 (epha2), and the apoptosis inhibitor protein survivin, combined with the adjuvant tetanus toxoid (tt)-derived helper t-cell peptide, and emulsified in the immunoadjuvant montanide isa-51, with potential immunostimulating and antineoplastic activities. specifically, this vaccine contains the epitopes: il-13ralpha2 345-353:1a9v, which is an engineered peptide based on amino acids 345-353 of il-13ra2 where the amino acids at the first and ninth positions of the peptide have been replaced with alanine and valine, respectively, epha2 883-891, and survivin 96-104. upon administration, the hla-a2-restricted il-13ra2/epha2/survivin/tt t-helper epitopes-montanide 51 vaccine may stimulate a hla-a2-restricted cytotoxic t-lymphocyte (ctl) response against tumor cells that overexpress il-13ra2, epha2, or survivin, and results in tumor cell lysis. tt t-helper peptide binds to class ii major histocompatibility molecules (mhc) molecules as a nonspecific vaccine helper epitope, resulting in long-term immunopotentiation by increasing the helper t-cell response. montanide isa-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide monooleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. il-13ra2, epha2 and survivin, taas that are overexpressed in certain tumor cell types, play key roles in tumor cell proliferation. hla-a2 presents antigenic peptides to cd8+ t-cells; epitope design restricted to epitopes that bind most efficiently to hla-a2 may improve peptide immunogenicity.pBCAR3 Phosphopeptide-tetanus Peptide Vaccine|pBCAR3-phosphopeptide Plus Tet Vaccine
a vaccine composed of a phosphorylated peptide from the tumor associated antigen breast cancer anti-estrogen resistance-3 (bcar3) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. upon administration of pbcar3 phosphopeptide-tetanus peptide vaccine, the pbcar3 phosphopeptide may stimulate the immune system to mount a cytotoxic t-lymphocyte (ctl) response against phosphopeptide-containing tumor cells. the tetanus peptide serves as an immunoadjuvant and induces a helper t-cell response, which may help stimulate an immune response against the pbcar3-expressing melanoma tumor cells. bcar3 is upregulated in a variety of cancer cells.pBCAR3/pIRS2-Phosphopeptide-tetanus Peptide Vaccine|2-MpP Phosphopeptide-tetanus Peptide Vaccine
a vaccine composed of phosphorylated peptides from the tumor associated antigens breast cancer anti-estrogen resistance-3 (bcar3) and insulin receptor substrate-2 (irs2) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. upon administration of pbcar3/pirs2 phosphopeptide-tetanus peptide vaccine, the pbcar3/pirs2 phosphopeptide may stimulate the immune system to mount a cytotoxic t-lymphocyte (ctl) response against tumor cells expressing either phosphopeptide. the tetanus peptide serves as an immunoadjuvant and induces a helper t-cell response which may help stimulate an immune response against pbcar3 and pirs2-expressing melanoma tumor cells. bcar3 and irs2 are upregulated in a variety of cancer cells.Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine
a melanoma peptide vaccine complexed with tetanus toxoid with potential antineoplastic activity. peptide 946 contains a melanoma-specific epitope recognized by melanoma-specific cytotoxic t lymphocytes (ctl). in addition to the peptide 946 sequence, this vaccine contains tetanus toxin, a protein known to stimulate the induction of cd4+ t lymphocytes; it thereby enhances antigen processing and presentation. vaccination with the peptide 946-tetanus conjugate melanoma vaccine may produce antibodies as well as elicit a cytotoxic t lymphocyte (ctl) response in tumor cells expressing the 946 epitope, thereby decreasing tumor cell growth.Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine/QS21|p946-Tet p/QS21
a vaccine comprised of peptide 946, a gp100 peptide recognized by melanoma-specific cytotoxic t lymphocytes, conjugated with a modified t-helper epitope from tetanus toxoid and emulsified with qs21, a saponin vaccine adjuvant. (nci)pIRS2 Phosphopeptide-tetanus Peptide Vaccine|pIRS2-phosphopeptide Plus Tet Vaccine
a vaccine composed of a phosphorylated peptide from the tumor associated antigen insulin receptor substrate-2 (irs2) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. upon administration of pirs2 phosphopeptide-tetanus peptide vaccine, the pirs2 phosphopeptide may stimulate the immune system to mount a cytotoxic t-lymphocyte (ctl) response against phosphopeptide-containing tumor cells. the tetanus peptide serves as an immunoadjuvant and induces a helper t-cell response which may help stimulate an immune response against the pirs2-expressing melanoma tumor cells. irs2 is upregulated in a variety of cancer cells.Synthetic Breast Cancer Peptides-Tetanus Toxoid-Montanide ISA-51 Vaccine
a cancer vaccine comprised of multiple synthetic breast cancer peptides and the adjuvant tetanus toxoid helper peptide emulsified in the adjuvant montanide isa-51 with immunopotentiation activity. vaccination with this cancer vaccine may elicit a specific cytotoxic t-lymphocyte response against breast cancer cells. synthetic breast cancer peptides may stimulate the immune response against cells that produce breast cancer markers such as erbb2 (her2/neu) while tetanus toxoid helper peptide binds to class ii mhc molecules as a nonspecific vaccine helper epitope, resulting in a long-term immunopotentiation by increasing the helper t-cell response. montanide isa-51, also known as incomplete freund's adjuvant or ifa, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.Synthetic Breast Cancer Peptides-Tetanus Toxoid-Poly ICLC Vaccine
a cancer vaccine comprised of nine class i major histocompatibility complex (mhc)-restricted breast cancer associated peptides, the tetanus toxoid helper peptide and the toll-like receptor 3 (tlr3) agonist poly iclc, with potential immunostimulatory and antineoplastic activities. the nine peptides derived from six cancer associated proteins are epidermal growth factor receptor 2 (her2/neu), carcinoembryonic antigen (cea) and four cancer/testis antigens (ctas: mage-a1, -a3, -a10, and ny-eso-1). vaccination with this vaccine may elicit a specific cytotoxic t-lymphocyte (ctl) response against cells overexpressing these tumor associated antigens (taas). as a nonspecific t-helper epitope, tetanus toxoid helper peptide binds to class ii mhc and results in long-term immunopotentiation by increasing the helper t-cell response. poly iclc, the double-stranded rna molecules of polyinosinic-polycytidylic acid stabilized with poly l-lysine in carboxymethylcellulose, binds to tlr3 and induces the release of cytokines which may help boost the immune response against the taas.Tetanus
a serious infectious disorder that follows wound contamination by the gram-positive bacterium clostridium tetani. the bacteria produce a neurotoxin called tetanospasmin, which causes muscle spasm in the jaw and other anatomic sites.Tetanus and Diphtheria Toxoids Adsorbed|DECAVAC|Td|Td|Tetanus and Diphtheria Toxoids Adsorbed for Adult Use
a sterile, intramuscular suspension of alum (aluminum potassium sulfate)-precipitated toxoids indicated for active immunization for the prevention of tetanus and diphtheria for use in persons 7 years of age or older.Tetanus Neonatorum|Neonatal Tetanus|Neonatal Tetanus
a syndrome of generalized rigidity with muscle spasms and seizures in the neonatal period resulting from clostridium tetani toxin production.Tetanus Peptide Melanoma Vaccine
a vaccine consisting of peptides derived from melanoma-associated antigens and a modified t-cell epitope derived from tetanus toxoid. vaccination with this agent may stimulate a host cytotoxic and helper t-cell response against tumor cells expressing melanoma-associated antigens, resulting in decreased tumor growth. (nci04)Tetanus Toxoid Aluminum Phosphate Adsorbed Vaccine
a vaccine that contains detoxified tetanus toxin of clostridium tetani. aluminum phosphate is an adjunct that adsorbs the tetanus antigens to increase the half-life and immunogenicity of the vaccine.Tetanus Toxoid Helper Peptide|TETANUS TOXOID HELPER PEPTIDE|Tet
obtained by genetic engineering from the bacterial clostridium tetani toxoid, tetanus toxoid helper peptide qyikanskfigitel (amino acids 830-844) binds to class ii mhc molecules as a nonspecific vaccine helper epitope (adjuvant) and induces an increased (and long term) immune response by increasing the helper t-cell response. (nci05)Tetanus Toxoid Vaccine|TT|Tetanus Toxoid|tetanus toxoid
a preparation of formaldehyde-deactivated toxin isolated from the bacterium clostridium tetani. tetanus toxoid is used for booster injection and can stimulate the production of antitoxin antibodies. this agent may be used as an adjuvant in cancer vaccines.Tetanus-CMV Fusion Peptide Vaccine
a vaccine containing an inactivated epitope of tetanus toxin fused to a cytomegalovirus (cmv) peptide epitope, with potential anti-viral and immunomodulating activities. upon administration, tetanus-cmv fusion peptide may stimulate a cytotoxic t-lymphocyte (ctl) response against cmv in the cmv-infected host. tetanus toxin contains universal t cell helper epitopes.Therapeutic Prostate Cancer Peptide Vaccine TENDU|TENDU|TENDU Vaccine|TET-based Prostate Cancer Peptide Vaccine TENDU|Tetanus-epitope-targeting-based Prostate Cancer Peptide Vaccine TENDU
a peptide cancer vaccine, based on the tetanus-epitope targeting (tet)-platform, composed of as of yet undisclosed tumor-associated antigens (taas) that are specific for prostate cancer and a tetanus-based vaccine adjuvant in the same molecule, with potential immunomodulating and antineoplastic activities. upon administration, therapeutic prostate cancer peptide vaccine tendu may stimulate a potent cytotoxic t-lymphocyte (ctl) immune response against prostate cancer cells that express these taas, resulting in tumor cell lysis. the tetanus peptide may enhance the anti-tumor immune response.
Patient EducationClinical
Tetanus
Tetanus is a serious illness caused by Clostridium bacteria. The bacteria live in soil, saliva, dust, and manure. The bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert A35 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.
Questions About A35Overview
Is A35 (Other tetanus) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report other tetanus on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does A35 group to?
When other tetanus is the principal diagnosis on an inpatient stay, it groups to MS-DRG 867, 868, 869, with relative weights from 0.7297 to 2.0932 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of A35?
Under the General Equivalence Mappings, other tetanus converts to ICD-9-CM 037 (tetanus). The mapping is a direct match.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
